What is ALX Oncology Holdings Inc.'s (ALXO) StockRank?

MoatMap's StockRank for ALX Oncology Holdings Inc. (ALXO) is 17/100, with a Strong Sell signal. This is a composite score combining Quality (23), Value (31), and Momentum (46) factor ranks across MoatMap's universe of 25,000+ stocks.

Does ALX Oncology Holdings Inc. have an economic moat?

ALX Oncology Holdings Inc. (ALXO) has a Quality factor score of 23/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is ALX Oncology Holdings Inc. a buy, hold, or sell?

MoatMap's current signal for ALX Oncology Holdings Inc. (ALXO) is Strong Sell, based on a StockRank of 17/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.

What sector is ALX Oncology Holdings Inc. in?

ALX Oncology Holdings Inc. (ALXO) operates in the Healthcare sector, specifically the Biotechnology industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

ALXO

Strong SellSinker

ALX Oncology Holdings Inc. · Healthcare · United States · $277M · Avg Vol: $2M/d

StockRank

Get insider-trade alerts

P/E (TTM)

—

ROE

-80.6%

D/E

0.1x

Dividend %

—

COMPANY DESCRIPTION

ALX Oncology Holdings Inc. is a clinical-stage immuno-oncology company dedicated to developing novel therapies that block the CD47 checkpoint pathway to enhance the immune system's attack on cancer. Its lead product candidate, ALX148, is designed as a potent CD47 blocker with an improved safety profile, positioning the company as a focused innovator in a challenging yet high-potential oncology therapeutic area.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR	TTM
Revenue	0	0	0	0	—	—
EPS	-0.92	-1.39	-1.02	-0.77	—	-1.15
Shares	134.6M	134.6M	134.6M	134.6M	0.0%	138.3M
Debt	9.4M	9.6M	9.9M	9.7M	1.3%	11.0M
Equity	263.5M	189.7M	113.6M	26.0M	-53.8%	—
Op CF	-89.2M	-130.4M	-121.9M	-84.1M	—	-70.8M
Inv CF	-235.4M	44.7M	86.3M	82.6M	—	—
Fin CF	9.9M	59.3M	30.8M	0.4M	—	—

Loading 1Y...

PRICE (1Y)-2.6%

SMA 50SMA 200

$1.90

RSI (14)

44.2

52W High

$2.66

From 52W High

0.7%

SCORE BREAKDOWN

Quality

ROIC

-290.2%1.6

ROE

-80.6%11.9

GP/Assets

—N/A

Op. Margin

0.0%38.1

FCF/Assets

-80.9%3.1

Piotroski

29.5

Int. Cover

-50.0x5.9

D/E Ratio

0.08x65.1

Current Ratio

9.71x87.0

Value

P/E (TTM)

—N/A

EV/EBITDA

-1.8x25.0

P/FCF

—N/A

P/B

2.0x61.9

P/S

—N/A

Div Yield

—N/A

Momentum

52W High %

71%54.1

RS 6M

-24%35.7

SMA 50/200

1.11x76.7

EPS Rev 4W

0.0%34.4

EPS Rev 12W

0.0%41.6

EPS Improve

+53%56.9

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$277M

P/E (Forward)

-3.7x

Gross Margin

0.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ALXO are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
ALXO	ALX Oncology Holdings Inc.(you)	$277M	17	Strong Sell
FULC	Fulcrum Therapeutics, Inc.	$294M	17	Strong Sell
MGNX	MacroGenics, Inc.	$263M	17	Strong Sell
VNDA	Vanda Pharmaceuticals Inc.	$320M	18	Strong Sell
PYXS	Pyxis Oncology, Inc.	$269M	15	Strong Sell
ELDN	Eledon Pharmaceuticals, Inc.	$260M	15	Strong Sell
SION	Sionna Therapeutics, Inc.	$265M	14	Strong Sell
OBIO	Orchestra BioMed Holdings, Inc.	$312M	19	Strong Sell
FATE	Fate Therapeutics, Inc.	$291M	21	Sell
IMRX	Immuneering Corporation	$323M	19	Strong Sell

Peer medians: ROE -30.2% · P/E 27.0x · Gross margin 58.3%

ALX Oncology Holdings Inc. (ALXO): Stock Score Summary

ALX Oncology Holdings Inc. (ALXO) has a MoatMap StockRank of 17/100 based on Quality (23/100), Value (31/100), and Momentum (46/100) factor scores. The current signal is STRONG SELL.

Key Financial Metrics

Price	$1.90
Market Cap	$277M
P/E (Forward)	-3.74
Price/Book	2.04
Return on Equity	-80.6%
Return on Invested Capital	-290.2%
Debt/Equity	0.08x
Gross Margin	0.0%
Operating Margin	0.0%
Free Cash Flow	$-48M

ALX Oncology Holdings Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is ALX Oncology Holdings Inc.’s (ALXO) StockRank?: MoatMap’s StockRank for ALX Oncology Holdings Inc. (ALXO) is 17/100, with a Strong Sell signal. It is a composite of Quality (23), Value (31), and Momentum (46) factor ranks across MoatMap’s universe of 25,000+ stocks.
Does ALX Oncology Holdings Inc. have an economic moat?: ALX Oncology Holdings Inc. (ALXO) has a Quality factor score of 23/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is ALX Oncology Holdings Inc. a buy, hold, or sell?: MoatMap’s current signal for ALX Oncology Holdings Inc. (ALXO) is Strong Sell, based on a StockRank of 17/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.
What sector is ALX Oncology Holdings Inc. in?: ALX Oncology Holdings Inc. (ALXO) operates in the Healthcare sector, specifically the Biotechnology industry (United States).